ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "AtriCure, Inc." (ATRC) Report Updated: Apr 14, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"AtriCure, Inc." (ATRC)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Health Care Equipment & Supplies
Competitors: DHRM, ATRI, LMAT, ANIK

Stock Analysis

Rating: Monthly View

A
B
C
D
F
April May June July August September October November December January February March

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"AtriCure, Inc."© quotemedia

Company Profile

AtriCure, Inc., a medical device company, develops, manufactures, and sells cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac tissue. Its primary product line includes isolator synergy bipolar radio-frequency ablation clamps for open-heart procedures and minimally invasive procedures; ablation and sensing unit, a compact power generator that delivers bipolar radio-frequency (RF) energy; AtriCure switch box, a compact switch box providing the technology needed for the dual pulsing electrodes, and the ability to connect and toggle between multiple RF devices; isolator multifunctional pen, a disposable RF device enabling surgeons to toggle back and forth between temporary pacing, sensing, and stimulation and ablation; and coolrail linear ablation device, a disposable linear RF ablation device, which allows physicians to create an expanded cardiac ablation lesion set during minimally invasive procedures. The company also offers cryoablation system, which consists of various reusable and disposable devices, including the Frigitronics CCS-200 product line for cardiac ablation; and Cryo1, a disposable cryoablation device, as well as AtriClip system, which is designed to exclude the left atrial appendage by implanting the device during concomitant open surgical procedures from the outside of the heart. In addition, it sells enabling technologies, including Lumitip dissector to separate tissues to provide access to key anatomical structures targeted for ablation; and MicroPace ORLab system, a stimulating, mapping, and recording system enabling physicians to confirm the ablation lines being created are forming electrical barriers or lines of block. The company sells its medical devices to hospitals and medical centers in the United States and internationally. AtriCure, Inc. is headquartered in West Chester, Ohio.

Recent News: "AtriCure, Inc."